Liabeuf S, Lambert O, Metzger M, et al. - In patients with chronic kidney disease (CKD), researchers sought to analyze the prevalence and incidence (new users) of proton pump inhibitor (PPI) prescriptions and their relation to kidney outcomes and mortality. In a cohort of 3,023 nephrology outpatients with CKD stages 2‐5 at inclusion, drug prescriptions were prospectively collected. Over a median follow‐up of 3.9 years (interquartile range, 3‐4.2), there were 981/3,023 (32%) prevalent users (67 ± 13 years, 65% men) at baseline; 366/3,023 (12%) of them were prescribed PPI (new users). Three hundred fifty-four patients developed end‐stage kidney disease (ESKD) and 216 died prior to ESKD during follow‐up. Data reported that the adjusted HR for PPI prescription-related AKI was 2.89. It was common to see long-term prescription of PPI in CKD patients. The findings highlight the possible dangers of both acute and chronic kidney failure in these patients.